

Kazuki Hoshino, Ph.D, studied microbiology at Chiba University, Japan and he holds a PhD degree with research of mechanisms of action of quinolone antibacterials. He joined Daiichi Pharmaceutical Co., Ltd. in 1986, and was in charge of discovery research on quinolone antimicrobials (levofloxacin, sitafloxacin) and β -lactams. From 1995, he became responsible for the project discovering efflux pump inhibitors for *P. aeruginosa*, and worked as the leader of collaboration research with Microcide Pharmaceuticals Inc., US. After the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo, he had worked as the project leader of new quinolone antimicrobials and new antibiotics including antibodies, discovery stage, 2007-2012 and was director of the Research Group, Biological Res. Labs, 2009-2012. Then he was involved in the research and development of vaccines as the senior director of vaccine research group, in vaccine business strategy department of Daiichi Sankyo. He subsequently became vice president of vaccine research laboratories, Kitasato Daiichi Sankyo Vaccine Co., Ltd. , 2015-2017, then vice president, R&D planning & management department, and head of division, R&D division, Kitasato Daiichi Sankyo Vaccine. After the reorganization scheme of Kitasato Daiichi Sankyo Vaccine in 2019, he has worked for Daiichi Sankyo Biotech, Co., Ltd. as the vice president of technology department. He also has served on the AMR task force activities in the Japan Pharmaceutical Manufacturers Association (JPMA). From 2018, he has served as a member of the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership (GARDP) and a program officer in the department of research promotion division of infectious diseases research of the Japan Agency for Medical Research and Development (AMED).